Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 23:12:goae085.
doi: 10.1093/gastro/goae085. eCollection 2024.

New perspectives in hepatocellular carcinoma surveillance after hepatitis C virus eradication

Calvin Q Pan  1   2 , Andrew J Park  3   4   5 , James S Park  3   4
Affiliations
Review

New perspectives in hepatocellular carcinoma surveillance after hepatitis C virus eradication

Calvin Q Pan et al. Gastroenterol Rep (Oxf). .

Abstract

Achieving a sustained virologic response (SVR) through direct-acting antivirals for hepatitis C virus (HCV) infection significantly reduces the long-term risk of hepatocellular carcinoma (HCC), particularly in patients with advanced fibrosis (F3) or cirrhosis (F4). However, despite this improvement, the risks associated with HCC and the optimal surveillance strategies for patients who have achieved SVR remain topics of debate. This controversy is compounded by challenges in reliably staging liver fibrosis non-invasively, especially at advanced fibrosis (F3), and the unclear cost-effectiveness, modality, frequency, and duration of HCC surveillance in individuals with SVR but without cirrhosis. These factors contribute to significant variations in surveillance guidelines recommended by different professional societies. Therefore, there is a pressing need for an optimal surveillance strategy that is both simplified and cost-effective to facilitate wider adoption by clinicians. This review article evaluates the existing data, addresses ongoing controversies, and aims to provide new perspectives on HCC surveillance strategies for patients who have achieved SVR from HCV.

Keywords: advanced fibrosis; chronic HCV infection; direct-acting antivirals; hepatitis C virus; liver cancer surveillance; sustained virologic response.

PubMed Disclaimer

Conflict of interest statement

All authors have completed the ICMJE uniform disclosure form and have no other conflicts of interest to declare. C.Q.P. received institutional research grants from Gilead Sciences and Wuxi Hisky Medical Technologies Co., Ltd. Table 1.Recommendations from international guidelines on HCC surveillance after DAA therapyPre-DAA assessmentAASLDEASLAPASLF0–F2N/AN/AUS+tumor markersa every 6 months for 2 years, followed by annually indefinitelyF3NoUS±AFP every 6 months indefinitelyUS+tumor markersa every 6 months indefinitelyF4US±AFP every 6 months indefinitelyUS±AFP every 6 months indefinitelyUS+tumor markersa every 6 months indefinitelyAASLD = American Association for the Study of Liver Diseases, EASL = European Association for the Study of Liver, APASL = Asian Pacific Association for the Study of Liver, SVR = sustained virologic response, DAA = direct acting antiviral agents, TE = transient elastography, FIB-4 = Fibrosis-4 index, US = ultrasound, N/A = not available, AFP = alpha-fetoprotein, AFP-L3 = lens culinaris agglutinin-reactive AFP isoform, DCP = des gamma carboxy-prothrombin.aTumor markers: AFP, AFL-L3, DCP.

Figures

Figure 1.
Figure 1.
A simplified algorithm for the surveillance of hepatocellular carcinoma in patients who have achieved SVR after HCV treatment. The algorithm provides recommendations on the methods and interval of HCC surveillance based on the severity of pre-treatment fibrosis in patients with HCV who achieved SVR after DAA therapy.
See this image and copyright information in PMC

References

    1. McGlynn KA, Petrick JL, El-Serag HB.. Epidemiology of hepatocellular carcinoma. Hepatology 2021;73(Suppl 1):4–13. - PMC - PubMed
    1. De Mitri MS, Poussin K, Baccarini P. et al. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413–5. - PubMed
    1. El-Serag HB, Kanwal F.. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology 2014;60:1767–75. - PMC - PubMed
    1. Dennis BB, Naji L, Jajarmi Y, Ahmed A, Kim D.. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years. World J Gastroenterol 2021;27:4818–30. - PMC - PubMed
    1. World Health Organization . Global Health Sector Strategy on Viral Hepatitis, 2016–2021. Geneva, Switzerland: World Health Organization; 2016. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-... (15 April 2024, date last accessed).

LinkOut - more resources